Wechalekar Ashutosh D, Lachmann Helen J, Offer Mark, Hawkins Philip N, Gillmore Julian D
National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom.
Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627.
We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Patients received a median of 3 (range 1-6) cycles of bortezomib and 9 (45%) patients received concurrent dexamethasone. Three (15%) patients achieved complete hematologic responses, and a further 13 (65%) achieved partial responses. Fifteen (75%) patients experienced some degree of toxicity, which in 8 (40%) cases resulted in discontinuation of bortezomib. Bortezomib shows promise in the treatment of systemic AL amyloidosis.
我们报告了硼替佐米对20例AL淀粉样变性患者疗效的初步观察结果。这些患者的克隆性疾病尽管接受了中位数为3线的既往化疗（所有病例均包括沙利度胺联合治疗），但仍处于活动期。患者接受硼替佐米治疗的中位数为3个周期（范围1 - 6个周期），9例（45%）患者同时接受地塞米松治疗。3例（15%）患者达到完全血液学缓解，另有13例（65%）达到部分缓解。15例（75%）患者出现了一定程度的毒性反应，其中8例（40%）因毒性反应导致硼替佐米停药。硼替佐米在系统性AL淀粉样变性的治疗中显示出前景。
